Around 30-40% of patients with epilepsy are refractory to a single antiseizure medication (ASM) and are treated with multiple ASMs to manage the condition. This has led to an increased effort to better treatment and management strategies in this area such that it can improve seizure control, retention rates and adverse events for the patients on ASMs. In this digest, we have covered such key presentations that deal with these issues at AAN’21.